ON Holding AG vs uniQure N.V. Ordinary Shares — how do they compare? ON Holding AG trades at $35.28 (market cap $11.86B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: ON Holding AG is far larger — about 8× uniQure N.V. Ordinary Shares's market cap, and ON Holding AG is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 24 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| ONON | QURE | |
|---|---|---|
Market Cap | $11.86B | $1.48B |
Volume | 8,624,555 | 2,488,780 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $70.59 |
52-Week Low | $26.76 | $9.03 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $11.02B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
ONON trades at $35.49, up 0.4% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.44, and announced a $1 billion share buyback program through 2029 alongside ambitious long-term growth targets. Revenue for 2025 was $3.01 billion with a net income margin of 12.3% and robust cash flow from operations of $359.5 million.
The outlook is positive, driven by earnings momentum, strategic expansion, and shareholder returns, but risks include high valuation multiples and competitive pressures. Analyst consensus is strongly bullish with a $42.26 price target, suggesting potential upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →